Biotech · Private company · Madison, WI, US
Salus Discovery, LLC
Track this companyFree. Adds Salus Discovery, LLC to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards8
- 3STEP: A swab-seal-read assay for tuberculosis and RIF resistance enabled by autonomous extraction technologyFiscal year 2026 · $913.7KNIH RePORTER 5R44AI179588-03 · fetched Nov 12, 2026
- Flow Direct: Next Generation Urine LFA for TB Diagnosis in Point-of-Care SettingsFiscal year 2026 · $1MNIH RePORTER 5R44AI184104-03 · fetched Nov 12, 2026
- 3STEP: A swab-seal-read assay for tuberculosis and RIF resistance enabled by autonomous extraction technologyFiscal year 2025 · $1MNIH RePORTER 4R44AI179588-02 · fetched Nov 12, 2026
- Flow Direct: Next Generation Urine LFA for TB Diagnosis in Point-of-Care SettingsFiscal year 2025 · $916.2KNIH RePORTER 4R44AI184104-02 · fetched Nov 12, 2026
- 3STEP: A swab-seal-read, point-of-care nucleic acid test to address disparity in STI screening and preventionFiscal year 2024 · $275.7KNIH RePORTER 1R43AI181122-01 · fetched Nov 12, 2026
- 3STEP: A swab-seal-read assay for tuberculosis and RIF resistance enabled by autonomous extraction technologyFiscal year 2024 · $295.9KNIH RePORTER 1R44AI179588-01A1 · fetched Nov 12, 2026
- Flow Direct: Next Generation Urine LFA for TB Diagnosis in Point-of-Care SettingsFiscal year 2024 · $300KNIH RePORTER 1R44AI184104-01A1 · fetched Nov 12, 2026
- Enhancing Pediatric Diagnosis of Tuberculosis with FLOW TechnologyFiscal year 2024 · $818.5KNIH RePORTER 5R44HD101201-03 · fetched Nov 12, 2026